[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 50 of about 50
31. Morris JC, Waldmann TA: Antibody-based therapy of leukaemia. Expert Rev Mol Med; 2009;11:e29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibody-based therapy of leukaemia.
  • Over the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma.
  • Currently, only two monoclonal antibodies - the anti-CD33 immunotoxin gemtuzumab ozogamicin and the CD52-directed antibody alemtuzumab - are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively.
  • Although not approved for such treatment, alemtuzumab is also active against T cell prolymphocytic leukaemia, cutaneous T cell lymphoma and Sézary syndrome, and adult T cell leukaemia and lymphoma.
  • In addition, rituximab has demonstrated activity against B cell chronic lymphocytic and hairy cell leukaemia.
  • Monoclonal antibodies targeting CD4, CD19, CD20, CD22, CD23, CD25, CD45, CD66 and CD122 are now being studied in the clinic for the treatment of leukaemia.
  • Improved interactions with Fc receptors on immune effector cells can enhance destruction of target cells through antibody-dependent cellular cytotoxicity and complement-mediated cell lysis.
  • The antibodies can also be armed with cellular toxins or radionuclides to enhance the destruction of leukaemia cells.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hematologic Neoplasms / therapy. Immunologic Factors / therapeutic use. Immunotoxins / therapeutic use. Leukemia / therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788782.001).
  • [ISSN] 1462-3994
  • [Journal-full-title] Expert reviews in molecular medicine
  • [ISO-abbreviation] Expert Rev Mol Med
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Immunologic Factors; 0 / Immunotoxins
  • [Number-of-references] 193
  •  go-up   go-down


32. Pisipati S, Lucas G, Pearce I: Leukaemia diagnosed as a consequence of haematuria assessment: a case report. Cases J; 2009;2:9289
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukaemia diagnosed as a consequence of haematuria assessment: a case report.
  • INTRODUCTION: T-cell prolymphocytic leukaemia is a rare condition that constitutes around 2% of cases of small lymphocytic leukaemia in adults.
  • CASE PRESENTATION: We report a 55-year-old male who was diagnosed with T-cell prolymphocytic leukaemia following investigations for microscopic haematuria.
  • Splenomegaly was identified on a plain abdominal radiograph and intravenous urography, thus triggering further investigations and diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20126319.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2815651
  •  go-up   go-down


33. Tempescul A, Feuerbach J, Ianotto JC, Dalbies F, Marion V, Le Bris MJ, De Braekeleer M, Berthou C: A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. Ann Hematol; 2009 Jan;88(1):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
  • [MeSH-major] Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols. Leukemia, Prolymphocytic, B-Cell / drug therapy. Mitoxantrone. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654781.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


3
Advertisement
4. Dixit M, Choudhuri G, Mittal B: Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study. Hepatol Res; 2006 Sep;36(1):61-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study.
  • INTRODUCTION: To identify high risk alleles for gallstone disease, we analyzed association of LDLRAvaII, LRPAP1 insertion/deletion, CETPTaqI B, and LPLHindIII polymorphisms with gallstone disease.
  • RESULTS: LRPAP1 gene insertion/deletion polymorphism was found to be significantly associated with gallstone disease.
  • Genotype II was conferring significant risk for gallstone disease in females only (P=0.019; OR 2.577, 95% CI 1.144-5.806).
  • LDLRAvaII, CETPTaqI B, and LPLHindIII polymorphisms were not found to be associated with gallstone disease either at genotype or allele level.
  • CONCLUSIONS: LRPAP1, II genotype carrier females may have increased risk for gallstone disease.
  • On the other hand, LDLR AvaII, CETP TaqI B, and LPL HindIII polymorphisms may not be associated with gallstone disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837242.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


35. Huh YO, Lin KI, Vega F, Schlette E, Yin CC, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV: MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol; 2008 Jul;142(1):36-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis.
  • Chromosomal translocations that involve MYC, characteristic of Burkitt lymphoma, are rare in chronic lymphocytic leukaemia (CLL).
  • Six cases were classified as CLL with increased prolymphocytes (CLL/PL; prolymphocytes 10-55%), and two were classified as CLL in prolymphocytic transformation (CLL/PT; prolymphocytes >55%).
  • Two developed Epstein-Barr virus (EBV)-associated diffuse large B-cell lymphomas (DLBCL) that were clonally unrelated to the CLL.
  • At follow-up, two patients are alive, four died of underlying disease, one died of EBV-associated DLBCL, and one died of an unrelated cancer.
  • [MeSH-major] Genes, myc / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Female. Humans. Immunophenotyping. Lymphoid Progenitor Cells / pathology. Male. Middle Aged. Mutation / genetics. Prognosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477041.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Osuji N, Matutes E, Dearden C, Catovsky D: Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia. Br J Haematol; 2005 Mar;128(5):645-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia.
  • The effect of pregnancy on T-cell large granular lymphocyte (LGL) leukaemia has not been previously described.
  • We retrospectively reviewed the clinical features of three patients with T-cell LGL leukaemia; each of them had one or more pregnancies during disease evolution.
  • A similar effect, induced by exogenous progesterone in one patient, suggests a role for progesterone in overcoming mechanisms of neutropenia in this disease.
  • Pregnancy thus appears to have a beneficial effect on neutrophil count in T-cell LGL leukaemia.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / immunology. Pregnancy Complications, Neoplastic / immunology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725086.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4G7DS2Q64Y / Progesterone; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


37. Martinez-Gallo M, Puy C, Ruiz-Hernandez R, Rodriguez-Arias JM, Bofill M, Nomdedeu JF, Cigudosa JC, Rodriguez-Sanchez JL, de la Calle-Martin O: Severe and recurrent episodes of bronchiolitis obliterans organising pneumonia associated with indolent CD4+ CD8+ T-cell leukaemia. Eur Respir J; 2008 Jun;31(6):1368-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe and recurrent episodes of bronchiolitis obliterans organising pneumonia associated with indolent CD4+ CD8+ T-cell leukaemia.
  • It can mimic infectious pneumonia but diagnosis is suspected when there is no response to multiple antibiotic treatment, and blood and sputum cultures are negative for microorganisms.
  • However, T-cell receptor Vbeta chain analysis indicated clonal rearrangement, and cytogenetic studies displayed chromosomic alterations that were similar to clonal proliferation observed in ataxia-telangiectasia and T-prolymphocytic leukaemia.
  • [MeSH-major] Cryptogenic Organizing Pneumonia / complications. Leukemia, T-Cell / complications. Leukemia, T-Cell / diagnosis

  • Genetic Alliance. consumer health - Bronchiolitis Obliterans.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18515560.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


38. Troussard X, Cornet E: Outline for writing an article for current treatment options in oncology: splenic lymphoma with villous lymphocytes. Curr Treat Options Oncol; 2007 Apr;8(2):97-108
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SLVL is a rare leukemic and indolent B-cell chronic lymphoproliferative disorder (B-CLPD) that we have to differentiate from hairy cell leukemia (HCL), B prolymphocytic leukemia (B-PLL) and follicular lymphoma (FL).
  • However, the diagnosis can be difficult to make on morphological criteria, especially in patients without absolute lymphocytosis.
  • SLVL has a relatively clinical benign course but a few patients could require treatment, because of a symptomatic splenomegaly and/or a severe cytopenia.
  • [MeSH-major] B-Lymphocytes / pathology. Lymphoma, B-Cell / therapy. Splenic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2002 Jun;3(1):41-7 [12141954.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1950-6 [10706860.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1558-62 [8123845.001]
  • [Cites] Lancet. 1992 Sep 5;340(8819):575-7 [1355156.001]
  • [Cites] Br J Haematol. 2003 Mar;120(5):759-64 [12614206.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):712-21 [9674745.001]
  • [Cites] Br J Haematol. 1998 Mar;100(3):609 [9504654.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4643-9 [16493005.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3552-8 [11369650.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2050-7 [15389479.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):158-61 [9359516.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):513-7 [16049984.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):404-12 [12877667.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):392-8 [16480431.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1603-7 [7888678.001]
  • [Cites] Eur J Haematol. 2002 Aug;69(2):112-4 [12366716.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2727-37 [14630827.001]
  • [Cites] J Clin Pathol. 1992 Dec;45(12):1111-3 [1479039.001]
  • [Cites] J Clin Pathol. 1987 Jun;40(6):642-51 [3497180.001]
  • [Cites] Leuk Res. 1996 Nov-Dec;20(11-12):909-13 [9009248.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1212-3 [9886348.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):600-4 [10086800.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3828-34 [7949139.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):731-6 [8652403.001]
  • [Cites] Haematologica. 2005 Apr;90(4):470-8 [15820942.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jan;36(1):57-69 [12461750.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1736-40 [9563492.001]
  • [Cites] Br J Haematol. 1993 Nov;85(3):487-91 [8136270.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jul 1;96(1):13-6 [9209463.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2659-61 [12239182.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):113-7 [11426611.001]
  • [Cites] Int J Hematol. 2005 Jun;81(5):413-6 [16158822.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1997 Mar-Apr;91(2):171-4 [9196759.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1648-54 [12176884.001]
  • [Cites] Blood Rev. 2005 Jan;19(1):39-51 [15572216.001]
  • [Cites] Br J Haematol. 1991 Jun;78(2):206-9 [2064958.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):134-40 [16405434.001]
  • [Cites] Leukemia. 2000 Apr;14(4):573-5 [10764141.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1924-5 [15385943.001]
  • [Cites] Eur J Haematol. 2005 Aug;75(2):130-5 [16000129.001]
  • (PMID = 17634839.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


39. Nguyen-Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff-Tavernier M, Ong J, Berger R, Leblond V, Merle-Béral H: Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. Cancer Genet Cytogenet; 2005 May;159(1):74-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin.
  • Burkitt-type acute leukemia cells were present in the bone marrow of a patient with B-prolymphocytic leukemia diagnosed from peripheral blood cell morphology.
  • These data indicated the common origin of the two coexisting leukemias and are the first example of such occurrence in a leukemic patient.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Prolymphocytic / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic
  • [MeSH-minor] Bone Marrow / pathology. Cell Lineage. Cytogenetic Analysis. Female. Gene Rearrangement. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860362.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Zhang YN, Zhou XG, Zhang SH, Wang P, Zhang CH, Huang SF: [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2005 Apr;34(4):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms].
  • OBJECTIVE: To describe the relative frequency, morphologic features, immunophenotype and clinical data of different types of B-cell non-Hodgkin lymphoma (B-NHL) and to evaluate the practical application of the 2001 World Health Organization (WHO) classification of lymphoid neoplasms.
  • Diffuse large B-cell lymphoma, extranodal marginal zone lymphoma and follicular lymphoma were the commonest subtypes, accounting for 51.2% (189 cases), 14.9% (55 cases) and 10.6% (39 cases) of all cases respectively.
  • B-cell prolymphocytic leukemia and hairy cell leukemia were not identified.
  • When comparing the diagnosis based on morphologic examination alone with the diagnosis based on both morphology and immunophenotype, there was a 80% concordance rate.
  • Immunohistochemical study was helpful in reaching the correct diagnosis in many cases and could improve the overall diagnostic accuracy by about 20%.
  • CONCLUSIONS: Amongst cases of B-NHL, diffuse large B-cell lymphoma is the commonest subtype, followed by MALToma and follicular lymphoma.
  • While morphologic examination forms the basis for lymphoma diagnosis, immunohistochemical study also plays an important role in further subtyping.
  • A combination of both modalities are sufficient for arriving at an accurate diagnosis in most cases of B-NHL, in keeping with the recommendation of the 2001 WHO classification of lymphoid neoplasms.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / classification

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091170.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD43; 0 / Antigens, CD79
  •  go-up   go-down


41. Mahmoud IS, Sughayer MA, Mohammad HA, Awidi AS, EL-Khateeb MS, Ismail SI: The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer; 2008 Aug 5;99(3):488-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.
  • Despite the major role of the AKT/PKB family of proteins in the regulation of many growth and survival mechanisms in the cell, and the increasing evidence suggesting that AKT disruption could play a key role in many human malignancies, no major mutations of AKT genes had been reported, until very recently when Carpten et al reported a novel transforming mutation (E17K) in the pleckstrin homology domain of the AKT1 gene in solid tumours.
  • Considering the importance of the PI3K/AKT pathway in mediating survival and antiapoptotic signals in the B-cell types of chronic lymphocytic leukaemia (CLL) and acute lymphoblastic leukaemia (ALL), we sequenced the AKT1 exon 3 for the above mentioned mutation in 87 specimens, representing 45 CLLs, 38 ALLs and 4 prolymphocytic leukaemia (PLL) cases, which are all of B-cell origin.
  • We conclude that this mutation is not a major event in B-cell-derived lymphoid leukaemias.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Transformation, Neoplastic / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Promyelocytic, Acute / genetics. Point Mutation. Proto-Oncogene Proteins c-akt / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Cell Signal. 2002 May;14(5):381-95 [11882383.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2969-76 [11929788.001]
  • [Cites] Leuk Lymphoma. 2002 Aug;43(8):1663-71 [12400610.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 11;1697(1-2):3-16 [15023346.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):733-42 [15158095.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1391-400 [15175625.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Jul;74(7):3065-7 [197531.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1259-64 [2832508.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4820-7 [15728130.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):273-85 [15986137.001]
  • [Cites] Adv Cancer Res. 2005;94:29-86 [16095999.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7435-42 [16288290.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7455-64 [16288292.001]
  • [Cites] Oncology. 2006;70(4):285-9 [17047397.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1473-9 [16940331.001]
  • [Cites] Leukemia. 2007 Jan;21(1):110-20 [17024114.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):439-44 [17611497.001]
  • [Cites] Ann Diagn Pathol. 2007 Oct;11(5):363-89 [17870025.001]
  • [Cites] Cytogenet Genome Res. 2007;118(2-4):310-9 [18000385.001]
  • [Cites] Blood. 2008 Jan 15;111(2):846-55 [17928528.001]
  • [Cites] Br J Haematol. 2008 Feb;140(3):344-7 [18053070.001]
  • [Cites] Acta Neuropathol. 2008 Mar;115(3):367-8 [18172656.001]
  • [Cites] Cell Cycle. 2008 Mar 1;7(5):665-9 [18256540.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1533-5 [18392055.001]
  • [Cites] Br J Haematol. 2008 May;141(5):742-3 [18410456.001]
  • (PMID = 18665177.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2527790
  •  go-up   go-down


42. Mahshid Y, Lisy MR, Wang X, Spanbroek R, Flygare J, Christensson B, Björkholm M, Sander B, Habenicht AJ, Claesson HE: High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes. BMC Immunol; 2009;10:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to better understand and define the role of 5-LO in B cells, we investigated the expression of 5-LO mRNA and protein in subsets of B cells from human tonsils and different types of B cell lymphoma.
  • This pattern of 5-LO expression was preserved in malignant lymphoma with high expression in mantle B cell lymphoma (MCL) and weak or no expression in follicular lymphoma.
  • Primary leukemized MCL, so called B-prolymphocytic leukaemia cells, and MCL cell lines also expressed 5-LO and readily produced LTB4 after activation.
  • [MeSH-major] Arachidonate 5-Lipoxygenase / biosynthesis. B-Lymphocyte Subsets / enzymology. B-Lymphocytes / enzymology. Leukemia, Prolymphocytic, B-Cell / enzymology. Lymphoma, Follicular / enzymology. Lymphoma, Mantle-Cell / enzymology
  • [MeSH-minor] Blotting, Western. Cell Differentiation. Cell Line. Cell Transformation, Neoplastic. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Leukemic. Humans. Immunity, Cellular. Immunologic Memory. Immunophenotyping. Leukotriene B4 / secretion. Lymphocyte Activation. Microscopy, Fluorescence. Palatine Tonsil / cytology. Palatine Tonsil / immunology. Polymerase Chain Reaction. Signal Transduction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30531-6 [10851239.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3857-65 [11090070.001]
  • [Cites] Curr Opin Oncol. 2001 Sep;13(5):342-7 [11555710.001]
  • [Cites] J Leukoc Biol. 2001 Nov;70(5):830-8 [11698504.001]
  • [Cites] Curr Opin Hematol. 2002 Jan;9(1):56-62 [11753079.001]
  • [Cites] Blood. 2003 May 15;101(10):4047-54 [12637326.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):123-34 [12895595.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1880-90 [12970790.001]
  • [Cites] Nat Immunol. 2003 Oct;4(10):982-90 [12949531.001]
  • [Cites] Nat Immunol. 2003 Oct;4(10):974-81 [12949532.001]
  • [Cites] Nat Immunol. 2003 Oct;4(10):965-73 [12949533.001]
  • [Cites] Cancer Treat Res. 2004;121:145-65 [15217209.001]
  • [Cites] Nature. 1980 Jul 17;286(5770):264-5 [6250050.001]
  • [Cites] J Immunol. 1985 Aug;135(2):1357-60 [2861228.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Jul 15;178(1):302-8 [1648910.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3521-5 [1314391.001]
  • [Cites] Int J Immunopharmacol. 1992 Apr;14(3):441-9 [1319964.001]
  • [Cites] Cell Immunol. 1994 Jun;156(1):124-34 [8200030.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3689-96 [8204893.001]
  • [Cites] J Biol Chem. 1994 Sep 2;269(35):22059-66 [8071328.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2035-46 [7738170.001]
  • [Cites] Br J Haematol. 1995 Jul;90(3):585-94 [7646998.001]
  • [Cites] Eur J Biochem. 1995 Aug 15;232(1):37-46 [7556168.001]
  • [Cites] Eur J Biochem. 1996 Nov 15;242(1):90-7 [8954158.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8276-80 [9079648.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):663-8 [9435249.001]
  • [Cites] J Intern Med. 1999 Mar;245(3):205-27 [10205583.001]
  • [Cites] Nature. 1999 Jun 24;399(6738):789-93 [10391245.001]
  • [Cites] J Immunol. 1999 Oct 15;163(8):4150-9 [10510350.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1274-9 [15454480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13164-9 [16135563.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40609-16 [16230355.001]
  • [Cites] EMBO J. 2006 Oct 4;25(19):4615-27 [16990797.001]
  • [Cites] Immunology. 2007 Oct;122(2):157-66 [17484769.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):750-62 [17891190.001]
  • (PMID = 19134178.001).
  • [ISSN] 1471-2172
  • [Journal-full-title] BMC immunology
  • [ISO-abbreviation] BMC Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1HGW4DR56D / Leukotriene B4; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  • [Other-IDs] NLM/ PMC2631017
  •  go-up   go-down


43. Abraham S, Braun RP, Matthes T, Saurat JH: A follow-up: previously reported apparent lymphomatoid contact dermatitis, now followed by T-cell prolymphocytic leukaemia. Br J Dermatol; 2006 Sep;155(3):633-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A follow-up: previously reported apparent lymphomatoid contact dermatitis, now followed by T-cell prolymphocytic leukaemia.
  • [MeSH-major] Dermatitis, Allergic Contact / diagnosis. Eyelid Diseases / diagnosis. Leukemia, Prolymphocytic / diagnosis. Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Fatal Outcome. Female. Humans. Leukemic Infiltration / diagnosis. Pseudolymphoma / diagnosis. Skin / pathology

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Dermatol. 2000 Aug;143(2):411-4 [10951155.001]
  • (PMID = 16911299.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


44. Curtin NJ, Schwarer AP: Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibility. Clin Lab Haematol; 2005 Jun;27(3):206-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibility.
  • We present a 54-year-old man who underwent human leucocyte antigen-identical sibling nonmyeloablative peripheral blood stem cell transplant for primary refractory T-cell prolymphocytic leukaemia (T-PLL).
  • [MeSH-major] ABO Blood-Group System / adverse effects. Acute Kidney Injury / etiology. Blood Group Incompatibility / complications. Hematopoietic Stem Cell Transplantation / adverse effects. Hemolysis. Leukemia, Prolymphocytic / complications. Leukemia, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938729.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


45. Dearden CE, Matutes E: Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract Res Clin Haematol; 2006;19(4):795-810
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alemtuzumab in T-cell lymphoproliferative disorders.
  • Recently it has been demonstrated in a number of clinical trials that alemtuzumab has clinical activity in mature T-cell diseases such as T-prolymphocytic leukaemia and cutaneous T-cell lymphoma, inducing responses in up to two thirds of heavily pre-treated relapsed/refractory patients.
  • Future studies will be directed towards alternative (subcutaneous) routes and schedules of administration, use as first-line therapy, combination strategies, and role of alemtuzumab to purge minimal residual bone-marrow disease prior to stem-cell transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997184.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Number-of-references] 67
  •  go-up   go-down


46. Reindl L, Bacher U, Dicker F, Alpermann T, Kern W, Schnittger S, Haferlach T, Haferlach C: Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms. Br J Haematol; 2010 Oct;151(1):25-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.
  • 14q-deletions have been repeatedly described in mature B-cell neoplasms, but not yet characterized in a larger cohort.
  • Based on chromosome banding analysis, the present study identified 47 del(14q) cases in 3054 mature B-cell neoplasms (1·5%) (chronic lymphocytic leukaemia [CLL]: 1·9%; CLL/prolymphocytic leukaemia [PL]: 9·0%; others: 0·2%).
  • In conclusion, the del(14q) is a rare recurrent alteration in diverse mature B-cell neoplasms, shows variable size but distinct clustering of breakpoints, and is associated with short time to treatment.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 14 / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20649559.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


47. Matutes E, Wotherspoon A, Catovsky D: Differential diagnosis in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol; 2007 Sep;20(3):367-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis in chronic lymphocytic leukaemia.
  • The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features.
  • In cases with atypical features, these investigations should be complemented with cytogenetics and/or histology to confirm the diagnosis and to exclude other B-cell disorders.
  • Cell-marker studies provide a robust foundation to establish the diagnosis as the lymphocytes have a distinct immunophenotypic signature.
  • Although no single antigen is exclusively expressed in CLL cells, when several markers are compounded into a scoring system the results allow firming up of the diagnosis.
  • Fluorescence in-situ hybridization (FISH) analysis also provides prognostic information, chiefly by detecting 17 (p53 locus) and 11q deletion, and may determine the type of therapy.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • [MeSH-minor] Bone Marrow / pathology. Diagnosis, Differential. Flow Cytometry. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Leukemia, Hairy Cell / diagnosis. Leukemia, Prolymphocytic / diagnosis. Lymphocytes / pathology. Prognosis. Spleen / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707827.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Beck C, Humpe A, Harder S, Schmid M, Horst HA: Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT: two very rare conditions in one patient. Ann Hematol; 2005 Sep;84(9):616-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT: two very rare conditions in one patient.
  • We report a 36-year-old male with myeloid/natural killer (NK)-cell precursor acute leukaemia with a complex aberrant karyotype, who was treated according to an acute-myeloid-leukaemia (AML) treatment protocol (idarubicine, cytarabine, and etoposide) followed by high-dose cytarabine consolidation and achieved complete remission.
  • He underwent allogeneic matched unrelated donor (MUD) peripheral blood stem-cell transplantation (PBSCT) and remained in remission throughout his remaining life.
  • This patient represents one of the few cases published achieving remission for a significant period of time after being diagnosed with myeloid/NK-cell precursor acute leukaemia, a very rare malignant disease.
  • In addition, the development of a myelodysplastic syndrome of donor origin is extremely rare and only very few cases are published worldwide.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Myeloid / pathology. Leukemia, Myeloid / therapy. Leukemia, Prolymphocytic, T-Cell / pathology. Myelodysplastic Syndromes / etiology. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Fatal Outcome. Humans. Infection. Male. Remission Induction / methods. Thrombocytopenia. Tissue Donors. Transplantation, Homologous. Treatment Outcome


49. Wanko SO, de Castro C: Hairy cell leukemia: an elusive but treatable disease. Oncologist; 2006 Jul-Aug;11(7):780-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hairy cell leukemia: an elusive but treatable disease.
  • Hairy cell leukemia (HCL) is a unique chronic lymphoproliferative disorder that can mimic or coexist with other clonal hematologic disorders and has been associated with autoimmune disorders.
  • It should be entertained as an alternative diagnosis in patients with cytopenias being assigned the diagnosis of aplastic anemia, hypoplastic myelodysplastic syndrome, atypical chronic lymphocytic leukemia, B-prolymphocytic leukemia, or idiopathic myelofibrosis.
  • The typical presentation is that of a middle-aged man with an incidental finding of pancytopenia, splenomegaly, and inaspirable bone marrow.
  • Relapsed disease after a prolonged remission can often be successfully retreated with the same initial agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / pathology. Leukemia, Hairy Cell / therapy

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880237.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; 9008-11-1 / Interferons
  •  go-up   go-down


50. Dungarwalla M, Matutes E, Dearden CE: Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol; 2008 Jun;80(6):469-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper.
  • Prolymphocytic leukaemias of B and T cell subtype are rare diseases.
  • Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor.
  • Purine analogues and monoclonal antibodies have shown efficacy in B-cell prolymphocytic leukaemia although further studies are warranted.
  • Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T-cell prolymphocytic leukaemia (T-PLL) but responses are still transient and further disease progression is inevitable.
  • While allogeneic stem cell transplant is an attractive option, due to the older age group of T-PLL patients the morbidity and mortality associated with the procedure is significant.
  • [MeSH-major] B-Lymphocytes / immunology. Leukemia, Lymphoid / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Disease Progression. Humans

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331594.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 49
  •  go-up   go-down






Advertisement